M. J. Drake Et Al. , "Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)," EUROPEAN UROLOGY , vol.70, no.1, pp.136-145, 2016
Drake, M. J. Et Al. 2016. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). EUROPEAN UROLOGY , vol.70, no.1 , 136-145.
Drake, M. J., Chapple, C., Esen, A. A., Athanasiou, S., Cambronero, J., Mitcheson, D., ... Herschorn, S.(2016). Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). EUROPEAN UROLOGY , vol.70, no.1, 136-145.
Drake, Marcus Et Al. "Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)," EUROPEAN UROLOGY , vol.70, no.1, 136-145, 2016
Drake, Marcus J. Et Al. "Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)." EUROPEAN UROLOGY , vol.70, no.1, pp.136-145, 2016
Drake, M. J. Et Al. (2016) . "Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)." EUROPEAN UROLOGY , vol.70, no.1, pp.136-145.
@article{article, author={Marcus J. Drake Et Al. }, title={Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)}, journal={EUROPEAN UROLOGY}, year=2016, pages={136-145} }